RxDoctor Payments Data

Lawrence Stokar, MD

Dermatology · White Oak, PANPI 1811998875

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $137,210 of the $173,547 with a category attached, or 79.1%. 41 manufacturers reported payments, led by AbbVie at 59.8% of the total. Reporting peaked in 2019 at $74,553 and has fallen 94.4% since, to $4,211 in 2025. Among dermatology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$173,547in general payments, 2019–2025

Across 1,312 payments — averaging $132.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$104K
  • Amgen$36K
  • Pfizer$19K
  • Journey Medical Corporation$2K
  • UCB, Inc.$2K
  • LEO Pharma Inc.$1K
  • plus $9K from 35 others

What the payments were for

  • Speaking & faculty fees$137,21079%
  • Travel & lodging$10,5066%
  • Food & beverage$25,61415%
  • Education$2170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$173,547 in reported general payments places this provider in the 95th percentile of 626 dermatology providers in Pennsylvania.

See all dermatology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$170,357
Medicare patients
573
Services billed
10,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa20$405,639
OtezlaApremilast37$177,481
SotyktuDeucravacitinib20$145,916
Enbrel SureclickEtanercept11$80,494
Betamethasone Dipropionate116$4,566
Ketoconazole250$4,002
Clobetasol Propionate94$3,951
Hydrocortisone240$3,048
Triamcinolone Acetonide317$2,982
Calcipotriene12$1,381
Doxycycline Hyclate95$1,265
Fluorouracil19$1,176
Clindamycin Phosphate36$1,011
Metronidazole27$939
Cephalexin74$920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$36,418$177,48137 claims
E.r. Squibb & Sons, L.L.C.Sotyktu$1,164$145,91620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 626 dermatology providers in Pennsylvania.

Other dermatology in White Oak

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →